- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia (CLL)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Venetoclax – March 2020
Venetoclax: Tablet 10 mg, Tablet 50 mg, Tablet 100 mg; Venclexta®
Last updated
17 July 2020